Amgen Inc. (NASDAQ:AMGN) Shares Bought by Syon Capital LLC

Syon Capital LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 42.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,947 shares of the medical research company’s stock after purchasing an additional 1,476 shares during the period. Syon Capital LLC’s holdings in Amgen were worth $1,425,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. BIP Wealth LLC raised its position in shares of Amgen by 2.6% in the 4th quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock valued at $360,000 after acquiring an additional 32 shares during the period. Southland Equity Partners LLC raised its position in shares of Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after acquiring an additional 34 shares during the period. Acropolis Investment Management LLC raised its position in shares of Amgen by 3.5% in the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after acquiring an additional 34 shares during the period. Opal Wealth Advisors LLC raised its position in shares of Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after acquiring an additional 34 shares during the period. Finally, Marino Stram & Associates LLC raised its position in shares of Amgen by 0.7% in the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after acquiring an additional 34 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 1.3 %

Shares of NASDAQ:AMGN traded down $3.63 during midday trading on Thursday, hitting $269.38. The stock had a trading volume of 1,760,656 shares, compared to its average volume of 2,827,059. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The business’s 50-day simple moving average is $275.77 and its 200-day simple moving average is $281.55. The company has a market cap of $144.49 billion, a P/E ratio of 21.86, a PEG ratio of 2.55 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the previous year, the business posted $4.09 earnings per share. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 19.42 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.34%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $329.00 price target on shares of Amgen in a research report on Wednesday, April 3rd. Truist Financial restated a “buy” rating and set a $320.00 target price on shares of Amgen in a report on Friday, April 12th. StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Leerink Partnrs downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Finally, UBS Group dropped their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.